Pipeline

We have a broad and differentiated pipeline of investigational drugs across our family of companies.

Cellular Background

10

positive Phase 3 trials since 2019

We have run numerous large successful international Phase 3 clinical trials.

Agnostic to therapeutic area and modality

Our pipeline includes innovative product candidates across numerous therapeutic areas.

Biologic · Immunovant
IMVT-1402
Graves' Disease
Registrational
Biologic · Immunovant
IMVT-1402
Difficult-to-Treat Rheumatoid Arthritis
Registrational
Biologic · Immunovant
IMVT-1402
Myasthenia Gravis
Registrational
Biologic · Immunovant
IMVT-1402
Chronic Inflammatory Demyelinating Polyneuropathy
Registrational
Biologic · Immunovant
IMVT-1402
Indication 5
Registrational
Biologic · Immunovant
IMVT-1402
Indication 6
Registrational
Biologic · Immunovant
Batoclimab
Myasthenia Gravis
Registrational
Biologic · Immunovant
Batoclimab
Thyroid Eye Disease
Registrational
Biologic · Immunovant
Batoclimab
Chronic Inflammatory Demyelinating Polyneuropathy
Registrational
Small Molecule · Priovant
Brepocitinib
Dermatomyositis
Registrational
Small Molecule · Priovant
Brepocitinib
Non-Infectious Uveitis
Registrational
Small Molecule · Priovant
Brepocitinib
Cutaneous Sarcoidosis
Proof of Concept
Inhaled · Pulmovant
Mosliciguat
Pulmonary Hypertension associated with Interstitial Lung Disease
Proof of Concept
video section decoration

Roivant CEO Matt Gline's presentation at the 2025 J.P. Morgan Healthcare Conference

Male Scientist in Lab
About Us

Interested in learning more?

Discover how our model aligns incentives to drive fast, high-quality execution and rigorous capital allocation.

Read more
Our Companies
Our Companies

Nimble, entrepreneurial Vants

Explore our diverse family of biopharmaceutical and health technology companies.

Read more